

Resource Summary Report

Generated by [nidm-terms](#) on Sep 21, 2026

University of Colorado Anschutz Medical Campus Cancer Center Pathology Shared Resource Molecular Pathology Core Facility

RRID:SCR_021995

Type: Tool

Proper Citation

University of Colorado Anschutz Medical Campus Cancer Center Pathology Shared Resource Molecular Pathology Core Facility (RRID:SCR_021995)

Resource Information

URL: <https://medschool.cuanschutz.edu/colorado-cancer-center/research/shared-resources/pathology/molecular-pathology>

Proper Citation: University of Colorado Anschutz Medical Campus Cancer Center Pathology Shared Resource Molecular Pathology Core Facility (RRID:SCR_021995)

Description: Molecular Pathology Section offers clinical grade sample processing and molecular testing for research cases. All services are performed in CLIA certified environment and all molecular assays are accompanied by full data analysis including bioinformatics analysis for NGS data.

Abbreviations: PSR-MP

Synonyms: Pathology Shared Resource - Molecular Pathology, Molecular Pathology

Resource Type: access service resource, core facility, service resource

Keywords: ABRF, USEDit, clinical grade sample processing, molecular testing, CLIA certified environment

Resource Name: University of Colorado Anschutz Medical Campus Cancer Center Pathology Shared Resource Molecular Pathology Core Facility

Resource ID: SCR_021995

Alternate IDs: ABRF_1318

Alternate URLs: <https://coremarketplace.org/?FacilityID=1318>

Record Creation Time: 20220421T050138+0000

Record Last Update: 20260919T195943+0000

Ratings and Alerts

No rating or validation information has been found for University of Colorado Anschutz Medical Campus Cancer Center Pathology Shared Resource Molecular Pathology Core Facility.

No alerts have been found for University of Colorado Anschutz Medical Campus Cancer Center Pathology Shared Resource Molecular Pathology Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Eule CJ, et al. (2025) Clinical features and mutational frequency of renal cell carcinoma from patients undergoing kidney transplant evaluation. *Frontiers in oncology*, 15, 1526545.

Maleddu A, et al. (2025) Novel PLEC-EML4-ALK Double Fusion Underlying Crizotinib Resistance in a Metastatic Inflammatory Myofibroblastic Tumor: A Case Report. *JTO clinical and research reports*, 6(5), 100791.

French JD, et al. (2024) Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(17), 3757.

Priest K, et al. (2023) Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway. *NPJ precision oncology*, 7(1), 9.